Ai Pathology Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

The AI pathology market sits at the intersection of digital pathology, computational imaging, and clinical diagnostics, encompassing deep-learning algorithms applied to whole-slide images of tissue samples. Total market value is estimated at around USD 1.375 billion in 2026, having reached approximately USD 1.22 billion in 2025, with the broader digital pathology market estimated between USD 1.07 billion and USD 1.83 billion depending on scope and methodology. Forecasts for AI-specific digital pathology vary widely, with projected CAGRs ranging from 8.5% to 25.56% depending on the segment definition and time horizon used.

Rising global cancer incidence is increasing the volume of tissue biopsies requiring expert analysis, intensifying pressure on already overstretched pathology services. At the same time, persistent shortages of trained pathologists in many regions are creating demand for automated tools that can assist with screening and quantification. Regulatory approvals for AI-based pathology products are accelerating, and healthcare providers are investing in whole-slide imaging infrastructure that generates the data required to deploy these algorithms at scale.

The market can be segmented by component into software, hardware, and services, with software representing the largest and fastest-growing share due to recurring licensing and cloud-based deployment models. By application, oncology, particularly breast, prostate, and colorectal cancer diagnosis, accounts for the dominant share, followed by infectious disease and toxicology pathology. North America leads the market today, supported by advanced healthcare IT infrastructure, strong R&D investment, and a favorable regulatory environment, while Asia-Pacific is the fastest-growing region due to large patient populations, expanding hospital networks, and rising digitization initiatives.

What are the recent trends and outlook?

Generative AI and foundation models trained on large pathology datasets are emerging as a transformative trend, enabling multi-purpose algorithms that can be adapted across cancer types and staining protocols. Companion diagnostic partnerships between AI pathology vendors and pharmaceutical companies are expanding, supporting biomarker-driven therapy selection in clinical trials and routine practice. Over the forecast period, the market is expected to benefit from clearer reimbursement pathways, deeper integration with laboratory and hospital information systems, and growing acceptance of AI-assisted rather than fully autonomous diagnostic workflows.

Named companies and quantified developments shaping the Ai Pathology market.

• •Roche - Roche announced an agreement to acquire PathAI for $750 million upfront, plus up to $300 million in milestone payments.
• •PathAI - PathAI raised $240M+ in funding.
• •Aidoc - Aidoc's platform has 20+ FDA clearances and raised over $200M.
• •Proscia - Proscia raised $50M in 2025 and works with 16 of 20 top pharma companies.